GAD2 and aceruloplasminemia: In contrast, preliminary reports suggest good efficacy for treatment-refractory autoimmune disorders, including autoimmune nervous system disease, but their safety profile is largely unknown.<h4>Objective</h4>To describe the first case of glutamic acid decarboxylase-65 (GAD65) antibody-mediated cerebellar ataxia (CA) successfully treated with CD19 CAR-T cells.<h4>Results</h4>A 33-year-old male was diagnosed with GAD65 antibody mediated CA in 2023.